Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Victoza (liraglutide) and Lantus (insulin glargine) are both injectable medications used to manage diabetes, but they work in different ways and are used for different types of diabetes. Victoza is a Glucagon-like peptide-1 (GLP-1) agonist that helps your body release more insulin, stop releasing extra sugar, and slow down digestion, making it useful for Type 2 diabetes and reducing heart-related risks. On the other hand, Lantus is a long-acting insulin that helps control blood sugar levels in both Type 1 and Type 2 diabetes by providing a steady release of insulin throughout the day. Victoza is typically injected once daily and can help with weight management, while Lantus is also injected once daily but is more focused on maintaining stable blood sugar levels. Victoza can cause side effects like nausea and vomiting, whereas Lantus may lead to low blood sugar and weight gain. Additionally, Victoza is not insulin, but Lantus is a form of insulin.
Victoza (liraglutide)
Lantus (insulin glargine)
Victoza (liraglutide)
Lantus (insulin glargine)
Summary of Victoza vs. Lantus
Summary for GLP-1 agonist
Prescription only
Victoza (liraglutide) is a medication that's injected once a day. It helps lower blood sugar levels in people 10 years and older with Type 2 diabetes when used with a nutritious diet and regular exercise. It can also help lower the risk of heart-related problems in adults with Type 2 diabetes and heart disease. Victoza (liraglutide) belongs to the drug class called GLP-1 agonists. The medication comes as single-dose prefilled pens and is injected under the skin. It can cause side effects like nausea, vomiting, diarrhea, and constipation. Victoza (liraglutide) is available as both a brand-name and generic medication.